Cargando…
Tendering and biosimilars: what role for value-added services?
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of bio...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Routledge
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968494/ https://www.ncbi.nlm.nih.gov/pubmed/32002174 http://dx.doi.org/10.1080/20016689.2019.1705120 |